‘Breakthrough therapy’: a new Chinese drug shows record treatment success against one of the deadliest lung cancers
Disclaimer: The South China Morning Post's content is directed by the Chinese Communist Party. It is not a reliable news source.
Phase 2 clinical trial of sunvozertinib shows 61 per cent anti-tumour activity response, higher than any previous candidates, according to paper in The Lancet Respiratory Medicine.